Hepatocyte growth factor is a prognostic marker in patients with colorectal cancer: a meta-analysis
Metrics: PDF 1320 views | HTML 1299 views | ?
Chao-yuan Huang1,*, Qian-yi Zhou1,*, Yue Hu2, Yi Wen1, Zhen-wen Qiu3, Man-guang Liang4, Jun-ling Mo4, Jian-hua Xu5, Cong Sun6, Feng-bin Liu3, Xin-lin Chen2
1The First Clinical College, Guangzhou University of Chinese Medicine, Guangzhou, China
2School of Basic Medical Science, Guangzhou University of Chinese Medicine, Guangzhou, China
3The First Affiliated Hospital, Guangzhou University of Chinese Medicine, Guangzhou, China
4The Second Clinical College, Guangzhou University of Chinese Medicine, Guangzhou, China
5The Second Affiliated Hospital, Guangzhou University of Chinese Medicine, Guangdong, China
6Zhongshan School of Medicine, Sun Yat-Sen University, Guangdong, China
*These authors contributed equally to this work
Feng-bin Liu, email: email@example.com
Xin-lin Chen, email: firstname.lastname@example.org
Keywords: hepatocyte growth factor, prognosis, marker, colorectal cancer, meta-analysis
Received: November 04, 2016 Accepted: February 12, 2017 Published: February 21, 2017
Hepatocyte growth factor (HGF) is a crucial factor associated with development, progression and metastasis of colorectal cancer (CRC). However, its prognostic value remains unclear. Thus studies referring to the correlation between HGF and CRC patients’ prognosis were included to explore the role of HGF in CRC. At last nine articles were included. The results showed that the over-expression of HGF was associated with a poor prognosis, presented through overall survival (OS, Hazard ratio (HR) = 2.50, 95% confidence interval (CI): 2.12–2.96) and disease-free survival (DFS, HR = 1.99, 95% CI: 1.59–2.50). Subgroup analysis indicated that no significant difference was found between the Asian countries (OS: HR = 2.37; DFS: HR = 2.02) and the non-Asian countries (OS: HR = 3.15; DFS: HR = 1.87), between the studies that used univariate analyses (OS: HR = 2.51; DFS: HR = 2.07) and those that used multivariate analyses (OS: HR = 2.65; DFS: HR = 1.78), and between metastatic CRC (OS: HR = 2.26; DFS: HR = 2.06) and stage I-IV CRC (OS: HR = 3.08; DFS: HR = 0.70). Our meta-analysis has shown that the over-expression of HGF is valuable in CRC prognosis evaluation. This conclusion should be further confirmed by large-sample cohort studies.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.